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Abstract
Background: We investigated the role of the central NMDA receptor NR2 subunits in the modulation of
nociceptive behavior and p-p38 MAPK expression in a rat model with compression of the trigeminal nerve root. To
address this possibility, changes in air-puff thresholds and pin-prick scores were determined following an
intracisternal administration of NR2 subunit antagonists. We also examined effects of NR2 subunit antagonists on
the p-p38 MAPK expression.
Results: Experiments were carried out using male Sprague-Dawley rats weighing (200-230 g). Compression of the
trigeminal nerve root was performed under pentobarbital sodium (40 mg/kg) anesthesia. Compression of the
trigeminal nerve root produced distinct nociceptive behavior such as mechanical allodynia and hyperalgesia.
Intracisternal administration of 10 or 20 μg of D-AP5 significantly increased the air-puff threshold and decreased
the pin-prick scores in a dose-dependent manner. The intracisternal administration of PPPA (1, 10 μg), or PPDA (5,
10 μg) increased the air-puff threshold and decreased the pin-prick scores ipsilateral as well as contralateral to the
compression of the trigeminal root. Compression of the trigeminal nerve root upregulated the expression of p-p38
MAPK in the ipsilateral medullary dorsal horn which was diminished by D-AP5, PPPA, PPDA, but not Ro25-6981.
Conclusions: Our findings suggest that central NMDA receptor NR2 subunits play an important role in the central
processing of trigeminal neuralgia-like nociception in rats with compression of the trigeminal nerve root. Our data
further indicate that the targeted blockade of NR2 subunits is a potentially important new treatments strategy for
trigeminal neuralgia-like nociception.
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Background
N-Methyl-D-aspartate (NMDA) receptors, which are
among the major mediators of fast excitatory neuro-
transmission in the central nervous system, have an
important role in long-term potentiation and depression,
synaptogenesis, synaptic plasticity, and neuronal death
[1,2]. The NMDA receptor (NR) family is composed of
seven subunits, NR1, NR2A-D and NR3A and B, which
are all products of separate genes [3]. Distinct NMDA
receptor subtypes differ in their sensitivity to a variety
of ligands, kinetic properties, and interactions with
intracellular proteins [4]. Expression of functional
recombinant NMDA receptors in mammalian cells
requires the co-expression of at least one NR1 subunit,
an essential channel-forming subunit, and one NR2 sub-
unit [1,2,5]. Receptor affinity for receptor agonists and
antagonists depends on the type of NR2 subunit [6,7].
Consistent with an increasing number of reports
implicating the importance of the NR2 subunit in pain
mechanisms, several experimental studies have demon-
strated the efficacy of selective NR2 subunit antagonists
[8-10]. Subcutaneous injection of formalin into the hind
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response, shows expression of NR2 subnits including
NR2A-D in the spinal cord [11]. Further, the intracister-
nal administration of (2R,4S)-4-(3-Phosphonopropyl)-2-
piperidinecarboxylic acid (PPPA), a competitive NR2A
antagonist, or (aR,bS)-a-(4-Hydroxyphenyl)-b-methyl-4-
(phenylmethyl)-1-piperidinepropanol maleate (Ro25-
6981), a selective NR2B antagonist, significantly
suppresses the number of scratches in the second phase
produced by subcutaneous injection of formalin in the
vibrissa pad of rats [12]. These results suggest that NR2-
containing NMDA receptors play an important role in
pain transmission and that their control may provide
novel therapeutic tools for future pain treatment.
Although chronic pain is dependent on NMDA recep-
tors, the clinical use of NMDA receptor antagonists is
of limited application due to the side effects resulting
from suppression of their physiological functions and
very narrow therapeutic indices [13]. However, the
spinal administration of Conantokin G, a selective inhi-
bitor of the NR2B subunit, produces potent antinocicep-
tion in formalin tests and the antinociceptive dose is
approximately 20 fold lower than those required to
impair motor function in a peripheral nerve injured ani-
mal model [14]. Highly potent NR2B-selective antago-
nists show good efficacy as pain killers and do not
induce the side effects usually seen with non-selective
NMDA receptor antagonists in a variety of animal mod-
els and humans [15,16]. These results suggest that selec-
tive NR2-related drugs have strong utility as analgesics
without producing side effects. However, limited data
are available concerning the role of central NR2 recep-
tors in the mechanical hypersensitivity of trigeminal
neuralgia.
Previous reports have demonstrated the active partici-
pation of central phospho-p38 mitogen-activated protein
kinase (p-p38 MAPK) in chronic pain resulting from
nerve injury. The spinal p38 MAPK, activated after
spinal cord injury [17], spinal nerve ligation [18], or tri-
geminal nerve injury [19], has been found to contribute
to development of nociceptive behavior in rats with neu-
ropathic pain. These results postulate that central p38
M A P Kp a t h w a yp l a ya ni m p o r t a n tr o l ei nt h ec e n t r a l
nociceptive processing of chronic pain.
Prolonged nociceptive behavior has been introduced
in rats following chronic compression of the trigeminal
ganglion [20] or nerve root (unpublished data). Mechan-
ical allodynia and hyperalgesia in the trigeminal territory
of the affected nerve are also induced in this animal
model, as is the upregulating of p-p38 MAPK expression
in the medullary dorsal horn. The purpose of our pre-
sent study was to investigate the role of the central NR2
subunits in the modulation of nociceptive behavior and
expression of p38 MAPK in rats with compression of
the trigeminal nerve root. In the experiments, changes
in air-puff thresholds and pin-prick scores in the rats
were determined following an intracisternal administra-
tion of D-2-amino-5-phosphonopentanoate (D-AP5), a
non-selective NMDA site antagonist, PPPA, a competi-
tive NR2A antagonist, Ro25-6981, a selective NR2B
antagonist, or (2S,3R)-1-(Phenanthren-2carbonyl)pipera-
zine-2,3-dicarboxylic acid (PPDA), a selective NR2C/
NR2D antagonist. Changes in p-p38 MAPK expression
in the medullary dorsal horn were also investigated
using immunohistochemical staining and western blot
analysis following the administration of NR2 subunit
antagonists.
Results
D-AP5, a non-selective NMDA site antagonist, attenuates
nociceptive behavior
The effects of D-AP5, a non-selective NMDA site
antagonist, on mechanical allodynia (A, B) and hyperal-
gesia (C, D) in rats with compression of the trigeminal
nerve root are shown in Figure 1. The intracisternal
administration of the vehicle did not affect air-puff
thresholds on either the ipsilateral or contralateral side.
However, 10 or 20 μg of D-AP5 increased the air-puff
threshold significantly in a dose-dependent manner (F(2,
21) = 6.272; P < 0.01). The contralateral air-puff thresh-
olds also increased significantly in a dose dependent
manner (F(2, 21) = 7.355; P < 0.01) following the intracis-
ternal administration of 10 or 20 μgo fD - A P 5 .T h e
anti-allodynic effects of D-AP5 were maintained for
three hours after injection. The intracisternal adminis-
t r a t i o no f1 0o r2 0μg of D-AP5 significantly decreased
the pin-prick scores ipsilateral (F(2, 21) = 7.355; P < 0.01)
as well as contralateral (F(2, 21) = 6.884; P < 0.01) to the
compression of the trigeminal nerve root. The anti-
hyperalgesic effects of D-AP5 were completely recovered
from at six hours after injection. However, the vehicle
injections did not affect the pin-prick scores in the rats.
PPPA, a competitive NR2A antagonist, attenuates
nociceptive behavior
The effects of PPPA, a competitive NR2A antagonist, on
mechanical allodynia (A, B) and hyperalgesia (C, D) in
t h er a tm o d e la r es h o w ni nF i g u r e2 .I n t r a c i s t e r n a l
administration of the vehicle did not affect the air-puff
thresholds on either ipsilateral or contralateral side.
However, 1 or 10 μg of PPPA increased air-puff thresh-
old significantly in a dose dependent manner both ipsi-
lateral (F(2, 21) = 16.460; P < 0.001) and contralateral
(F(2, 21) = 16.548; P < 0.001) to the compression of the
trigeminal nerve root. The anti-allodynic effects of
PPPA were maintained for two hours after 1 μgo f
PPPA and six hours after 10 μg of PPPA, respectively.
The intracisternal administration of PPPA at both of
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scores ipsilateral (F(2, 21) = 18.248; P < 0.001) and con-
tralateral (F(2, 21) = 13.965; P < 0.001) to the compres-
sion of the trigeminal nerve root. The anti-hyperalgesic
effects of PPPA were completely recovered at six hours
after the 10 μg PPPA injection. The vehicle injection did
not affect the pin-prick scores.
Ro25-6981, a selective NR2B antagonist, do not attenuate
nociceptive behavior
The effects of Ro25-6981, a selective NR2B antagonist,
on mechanical allodynia (A, B) and hyperalgesia (C, D)
in the model rats are shown in Figure 3. Neither the
intracisternal administration of vehicle nor 50 or 100 μg
of Ro25-6981 affected the air-puff thresholds on the
ipsilateral and contralateral sides. Moreover, neither
dose of Ro25-6981 affected the pin-prick scores in rats
with compression of the trigeminal nerve root.
PPDA, a selective NR2C/D antagonist, attenuates
nociceptive behavior
The intracisternal injection of 5 or 10 μg of PPDA a
selective NR2C/D antagonist significantly produced anti-
allodynic effects in a dose dependent manner on the
ipsilateral (F(2, 21) = 75.899; P < 0.001) and contralateral
(F(2, 21) = 85.304; P < 0.001) sides (Figure 4A, B). These
Figure 1 The antinociceptive effects of D-AP5 in rats with compression of the trigeminal nerve root. The effects of D-AP5, a non-
selective NMDA site antagonist, on mechanical allodynia (A, B) and hyperalgesia (C, D) in rats with compression of the trigeminal nerve root
(n = 8 in each treatment group). The intracisternal administration of vehicle did not affect air-puff thresholds in either the ipsilateral (A) or
contralateral (B) side. However, 10 or 20 μg injections of AP5 increased the air-puff threshold significantly in a dose-dependent manner on both
sides (A, B). These anti-allodynic effects of AP5 were maintained for three hours after injection. The intracisternal administration of 10 or 20 μgo f
AP5 also decreased the pin-prick scores ipsilateral (C) as well as contralateral (D) to the compression of the trigeminal nerve root. These anti-
hyperalgesic effects of AP5 were completely recovered by six hours after injection. Vehicle injections did not affect pin-prick scores in the subject
rats. *P < 0.05, vehicle-vs. AP-5-treated groups.
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the 5 μg doses of PPDA and three hours at the 10 μg
dose of PPDA. PPDA also produced significant anti-
hyperalgesic effects on the ipsilateral (F(2, 21) = 26.551;
P < 0.001) and contralateral (F(2, 21) = 16.184; P < 0.001)
sides at 5 and 10 μg doses, respectively (Figure 4C, D)
which were completely reversed at six hours after the
10 μg dose. The pin-prick scores were unaffected by the
injection of vehicle.
Effects of NR2 subunit antagonists on motor dysfunction
To next evaluate whether antinociceptive doses of NR2
subunit antagonists are associated with motor dysfunction,
a rotarod test was performed following the intracisternal
administration of AP5 (10, 20 μg), PPPA (1, 10 μg), Ro25-
6981 (50, 100 μg) and PPDA (5, 10 μg) (Table 1). The
intracisternal administration of vehicle did not produce
any motor dysfunction. In addition, neither Ro25-6981
nor low doses of PPPA (1 μg) affected the time course of
motor performance. However, other NR2 subunit antago-
nists produced measurable motor dysfunction. Although
low doses of AP5 (10 μg) and PPDA (5 μg) caused motor
dysfunction, the time course of motor performance was
completely recovered to pretreatment values within 0.5
and 1 hours after injection, respectively. However, high
doses of AP5 (20 μg) and PPDA (10 μg) produced
Figure 2 The antinociceptive effects of PPPA in rats with compression of the trigeminal nerve root. The effects of PPPA, a competitive
NR2A antagonist, on mechanical allodynia (A, B) and hyperalgesia (C, D) in rats with compression of the trigeminal nerve root (n = 8 in each
treatment group). The intracisternal administration of vehicle did not affect air-puff thresholds in either ipsilateral or contralateral side. However,
1o r1 0μg injections of PPPA significantly increased the air-puff threshold in a dose-dependent manner both ipsilateral (A) and contralateral (B)
to the compression of the trigeminal nerve root. The anti-allodynic effects of PPPA were maintained for one hour after a 1 μg injection of PPPA
and six hours after a 10 μg dose of PPPA. The intracisternal administration of 1 or 10 μg of PPPA also significantly decreased the pin-prick scores
on both sides (C, D). The anti-hyperalgesic effects of PPPA had completely recovered by six hours after the 10 μg PPPA injection. *P < 0.05,
vehicle-vs. PPPA-treated groups.
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after injection, respectively. The time course of motor per-
formance did not recover until six hours after the injection
of 10 μgo fP P P A .
NR2 subunit antagonists but not Ro25-6981 reduces up-
regulated p-p38 MAPK expression
The effects of NR2 subunit antagonists on the expres-
sion of p-p38 MAPK in the medullary dorsal horn of
our subject rat are shown in Figure 5. Compression of
the trigeminal nerve root significantly increased the
expression of p-p38 MAPK immunoreactivity in the
ipsilateral medullary dorsal horn. The intracisternal
administration of vehicle did not affect these p-p38
MAPKs (Figure 5B), but D-AP5 (10 μg), PPPA (1 μg),
and PPDA (5 μg) all suppressed the upregulation of
P-p38 MAPK expression in the medullary dorsal horn
(Figure 5C-E). Ro25-6981 (100 μg) had no effect (Figure
5F). Western blot analysis further demonstrated that the
increased p-p38 MAPK levels was significantly reversed
following the administration of all of the NR2 subunit
antagonists tested except for Ro25-6981 as compared
with vehicle treatment (Figure 5G, H).
Discussion
Our present analyses first demonstrate that the intracis-
ternal administration of NR2 subunit antagonists
produces antinociceptive effects in a rat model of a com-
pressed the trigeminal nerve root. These antinociceptive
doses also suppress p38 MAPK activation in the medul-
lary dorsal horn in subject rats. The antinociceptive
potency of the NR2 subunit antagonists tested was found
Figure 3 The antinociceptive effects of Ro25-6981 in rats with compression of the trigeminal nerve root. The effects of Ro25-6981, a
selective NR2B antagonist, on mechanical allodynia (A, B) and hyperalgesia (C, D) in rats with compression of the trigeminal root (n = 8 in each
treatment group). Neither the intracisternal administration of vehicle nor 50 or 100 μg of Ro25-6981 affected the air-puff thresholds on both the
ipsilateral (A) and contralateral (B) sides. Moreover, injections of 50 or 100 μg of Ro25-6981 did not affect pin-prick scores on either side (C, D).
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NR2C/NR2D antagonist, on mechanical allodynia (A, B) and hyperalgesia (C, D) in rats with compression of the trigeminal nerve root (n = 8 in
each treatment group). The intracisternal administration of vehicle did not affect air-puff thresholds in either the ipsilateral (A) or contralateral (B)
side. However, injections of 5 or 10 μg of PPDA produced significant anti-allodynic effects in a dose-dependent manner in both sides (A, B). The
anti-allodynic effects of PPDA were maintained for two hours after injection of 5 μg of PPDA and three hours after administration of the 10 μg
dose. The intracisternal administration of 5 or 10 μg of PPDA also produced significant anti-hyperalgesic effects on the ipsilateral (C) and
contralateral (D) side. The anti-hyperalgesic effects of PPPA were completely recovered by six hours after injection with 10 μg of PPPA. Vehicle
injections did not affect pin-prick scores in the subject rats. *P < 0.05, vehicle-vs. PPDA-treated groups.
Table 1 Effects of the intracisternal administration of NR antagonists on motor functions
Post injection time 30 min 1 hr 2 hr 3 hr 5 hr
Chemicals Dose (μg) The time of motor performance (min)
AP5 10 60 ± 30* 180 180 180 180
20 4 ± 2* 94 ± 36* 162 ± 28 180 180
PPPA 1 180 180 180 180 180
10 2 ± 1* 2 ± 1* 2 ± 1* 5 ± 2* 70 ± 39*
PPDA 5 32 ± 14* 81 ± 28* 180 180 180
10 4 ± 2* 5 ± 3* 30 ± 17* 57 ± 16* 180
The time course of motor performance (min) was evaluated using a rotarod test following the injection of NR2 antagonists. The time course of motor
performance prior to treatment and the cut-off time is 180 min. Neither intracisternal administration of vehicle nor Ro25-6981, a selective NR2B antagonist,
altered the time course of motor performance. There were 6 animals in each treatment group. * P < 0.05, compared with the vehicle-treated group.
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motor dysfunction side effects. These results suggest that
NR2 subunit antagonists have the potential utility as
novel agents for trigeminal neuropathic pain relief at an
appropriately managed dose.
Trigeminal neuralgia is characterized by episodes of
stabbing or electrical shock-like pain. Several theories of
the pathophysiology of this phenomenon have been
proposed to account for its clinical features. Vascular
compression of the trigeminal nerve root is known as
one of the major etiological aspects of trigeminal neural-
gia [21-23]. In patients with this disorder, prolonged
pain can be alleviated by surgical micro-vascular decom-
pression [21,24,25]. Although these reports have sug-
gested that the trigeminal nerve root plays an important
role in the underlying pathophysiology of trigeminal
Figure 5 The effects of NR2 subunit antagonists on the expression of p-p38 MAPK. Changes in the expression of p-p38 MAPK in
medullary dorsal horn of rats with compression of the trigeminal of nerve root following the administration of NR2 subunit antagonists (n = 5
in each treatment group). The intracisternal administration of vehicle did not affect p-p38 MAPK levels caused by compression of the trigeminal
nerve root (B). However, the intracisternal administration of AP5 (10 μg), PPPA (1 μg), or PPDA (5 μg) decreased p-p38 MAPK expression in the
medullary dorsal horn (C-E). However, Ro25-6981 (100 μg) did not affect p-p38 MAPK levels (F). Western blot analyses further confirmed that the
upregulation of p-p38 MAPK was significantly suppressed by all NR2 subunit antagonists tested except for Ro25-6981 (G, H). The total p38 (t-p38)
levels were used as the loading control. Scale bar, 50 μm. #P < 0.05, compared with the sham-treated group, *P < 0.05, compared with the
vehicle-treated group.
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are inferred from clinical observations rather than from
experimental manipulation. Our present study demon-
strates, however, that compression of the trigeminal
nerve root produces obvious nociceptive behavioral
changes in rats. Compression of the trigeminal nerve
root significantly decreased air-puff thresholds and
increased pin-prick stimulation scores on both the ipsi-
lateral and contralateral sides. Mechanical allodynia and
hyperalgesia presented on postoperative day 3 following
compression of the trigeminal nerve root and then per-
sisted for 30 days after surgery (unpublished data).
Consistent with the present data, which demonstrated
the antinociceptive effects of NR2 subunit antagonists in
rats, several previous experimental studies have shown
the participation of the NR2-selective NMDA receptor
in pain transmission in the central nervous system
[8-10]. Chronic constriction injury of the sciatic nerve
in rats produces a time-dependent upregulation of NR2
subunits of the NMDA receptor within the spinal cord
dorsal horn ipsilateral to the chronic constriction nerve
injury [26]. NR2A or NR2B antagonists injected intracis-
ternally have also been shown to block nociceptive
scratching behavior produced by subcutaneous injection
of formalin in the vibrissa pad of rats [12]. These results
suggest that central NR2 subunits play an important
role in pain transmission. However, our current data
indicate that NR2B subunit antagonists do not attenuate
nociceptive behavior, although NR2A or NR2C/D subu-
nit antagonists do inhibit mechanical allodynia and
hyperalgesia. These functional differences between NR2
subunits antagonist are supported by several previous
studies. NR2A in the spinal cord has different locations
at the cellular level compared with NR2B [27,28]. NR2A
subunits predominate at synapses, whereas NR2B subu-
nits are present extrasynaptically and do not participate
in synaptic transmission in adult rat lamina II neurons.
Neurons in lamina I have a higher mean ratio of NR2C/
D subunit receptors [29] and the maximal open prob-
ability of the NMDA receptor channel also differs for
each NR2 receptor subunit (NR2A-D) [30]. Moreover,
functional differences between the antinociceptive
actions of NR2 subunits may be caused by different ani-
mal models or species in addition to differential expres-
sion and electrical properties of NR2 subunits. Hence,
differential expression or distinct pharmacological and
biophysical properties of NR2 subunits may also under-
lie our present findings that the intracisternal adminis-
tration of PPPA, PPDA, but not Ro25-6981, produces
significant antinociceptive outcomes.
Previous studies have demonstrated that p38 MAPK is
activated in rats with neuropathic pain caused by spinal
nerve ligation [18] or spared nerve injury [31]. Moreover,
pretreatment with p38 MAPK inhibitors attenuated
increased p-p38 MAPK expression and nociceptive beha-
vior. These accumulating evidences also now suggest that
p38 MAPK is likely to contribute to the development of
pain hypersensitivity in animal models of neuropathic
pain [17-19]. Compression of the trigeminal nerve root
produces significant nociceptive behavior and upregu-
lates p-p38 MAPK expression in the ipsilateral medullary
dorsal horn in the current study. These results imply that
p38 MAPK is a key intracellular signal mediator involved
in the development of neuropathic pain including trigem-
inal neuralgia-like pain caused by compression of the tri-
geminal nerve root. Furthermore, our present analyses
show that intracisternal administration of D-AP5, PPPA,
and PPDA, but not Ro25-6981 attenuates the expression
of p-p38 MAPK, suggesting that specific NR2 subunit
NMDA receptors participate in the central transmission
of trigeminal neuropathic pain through p38 MAPK acti-
vation following compression of the trigeminal nerve
root.
The cellular mechanisms of NR2 involvement in pain
transmission are limited in availability. Small-diameter pri-
mary afferent fibers terminating in the dorsal horn express
NMDA receptors including NR2 subunits and the activa-
tion of presynaptic NMDA receptors causes the release of
substance P from primary afferents [32]. Notably, NR2
subunits are predominantly expressed on small-diameter
primary afferents [33]. These results suggest that presy-
naptic NR2 containing NMDA receptors, which can be
facilitated, prolong the transmission of nociceptive mes-
sages through the release of the neurotransmitters includ-
ing substance P, calcitonin gene-related peptide, or
glutamate in small-diameter primary afferent terminals
[32,33]. In contrast, phosphorylated NR1 subunit is signifi-
cantly upregulated in the ipsilateral dorsal horn in nerve-
injured rats, whereas no differences in the expression of
NR2A, NR2B, NR2C or the NR2D subunits have been
reported [34]. These data suggest that the phosphorylation
of the NR1 subunit correlates with the signs of neuropathy
(stimulus evoked pain-like behavior) and with persistent
pain following nerve injury. Hence, the role of NR1 in the
central processing of trigeminal neuralgia should be stu-
died further.
Since the spinal delivery of NMDA receptor antago-
nists was shown previously to inhibit the hyperexcitabil-
ity of spinal cord nociceptive neurons induced by C-fiber
stimulation [35,36], NMDA receptor antagonists have
been shown also to effectively alleviate pain-related beha-
vior in animal models and in clinical situations [37,38].
Although chronic pain depends on NMDA receptors, the
clinical use of NMDA receptor blockers is limited by the
resulting side effects [13]. In this regard, a reduced side
effect profile and an improved efficacy of specific NR2-
selective antagonists in animal pain models suggest that
they have the potential to treat pain in human patients
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induce the side effects in human usually seen with non-
selective NMDA receptor antagonists, even at the maxi-
mal neuroprotective doses [15,16]. Our present experi-
ments show that low doses of NR2 subunit antagonists,
which did not produce motor dysfunction or did so at
levels that recovered to normal within one hour, produce
a significant antinociception and decrease upregulation
of p-p 38 MAPK in rats with compression of the trigem-
inal nerve root. However, high doses of NR2 subunit
antagonists produced significant motor dysfunction upto
2 hours and 3 hours after injection. These results suggest
that low concentrations of NR2 subunit antagonists may
be potential treatments for trigeminal neuralgia-like noci-
ception, although high doses of these agents should be
avoided to reduce unwanted side effects in the clinic.
Conclusions
In conclusion, we show herein that the intracisternal
administration of NR2 subunit antagonists inhibits noci-
ceptive behavioral responsesa n dp 3 8M A P Ka c t i v a t i o n
in the medullary dorsal horn in rats with compression
of the trigeminal root. These results suggest that central
NR2 subunits play an important role in the central pro-
cessing of trigeminal neuralgia and that a targeted
blockade of the NR2 receptor is a potentially important
new treatments strategy for trigeminal neuralgia.
Methods
All procedures involving the use of animals were
approved by the Institutional Care and Use Committee
of the School of Dentistry, Kyungpook National Univer-
sity. Experiments involving the investigation of pain in
conscious animals were carried out in strict accordance
with the ethical guidelines of the International Associa-
tion for the Study of Pain and the National Institute of
Health Guide for the Care and Use of Laboratory
Animals.
Animals
Experiments were carried out on male Sprague-Dawley
rats weighing between 200 and 230 g. The animals were
maintained in a temperature-controlled room (23 ± 1°C)
with a 12/12 hr light-dark cycle (light on at 7:00 am).
All behavioral responses were measured in a blind
fashion.
Compression of the trigeminal nerve root
Compression of the trigeminal nerve root was per-
formed under pentobarbital sodium (40 mg/kg) anesthe-
sia. Anesthetized rats were mounted on a stereotaxic
frame (Model 1404; David Kopf Instruments, Tujunga,
CA) and a guide cannula (21 gauge) was implanted into
the left trigeminal nerve root. The Coordinates were as
follows: 7.2 mm posterior to the bregma, 2.45 mm lat-
eral from midline, and 8.0 mm ventral from the surface
of the skull. The injector (24 gauge) was connected to a
100 μl Hamilton syringe with polyethylene tube (PE 50,
Clay Adams, Parsippany, NJ) and was preheated in the
warm water bath (38°C). A 4% agar solution (10 μl) was
then administrated for 5 sec through the injector, which
extended 1 mm beyond the end of a guide cannula. The
injected agar was located on the dorsal surface of the
trigeminal nerve root to induce compression without
any injury during operation. The sham group received
no agar injections. After the injector and guide cannula
were removed, the incision was sutured. At the end of
each experiment, the compressed site of trigeminal
nerve root was confirmed. The animals were deeply
anesthetized with a lethal dose of pentobarbital sodium
and were perfused through the heart with phosphate
buffered saline. After perfusion, the brain was removed
and injection sites were examined using a stereoscope.
Only data from rats showing clear compression sites on
the trigeminal nerve root were used in the final analysis.
Evaluation of facial nociceptive behavior following
compression of the trigeminal nerve root
Mechanical allodynia
For behavioral observations, each rat was placed in a cus-
tomized observation cage in a darkened and noise-free
room and acclimated for at least 30 min. An evaluation of
withdrawal behavioral responses was performed after the
application of 10 successive trials of constant air-puff pres-
sure (4 sec duration and 10 sec intervals) on freely moving
rats, as previously described [20,40]. The intensity and
intervals of the air-puffs were controlled with a pneumatic
pump module (BH2 system; Harvard Apparatus, Holliston,
MA). The air-puffs were applied through a 26 gauge metal
t u b e( l e n g t h ,1 0c m )l o c a t e d1c mf r o mt h es k i na n dt h e
cut-off pressure was 40 psi. Allodynia was defined as the
decrease in the intensity of the air-puff threshold when
rats attempted to escape or showed an aggressive beha-
vioral response to air-puff stimulation. The thresholds
were determined as the air-puff pressure at which each rat
responded in 50% of the trials. Naïve animals did not
respond to less than 40 psi.
Mechanical hyperalgesia
Mechanical hyperalgesia was determined using the pin-
prick test after surgery as previously described [20,40].
Briefly, the rats were acclimated in an observation cage
before testing. The tip of a 0.2 mm diameter blunted
acupuncture needle (Needle No.3, Serin, Tokyo, Japan)
w a sp u s h e da g a i n s tt h ev i b r i s s ap a d ,u n t i lt h en e e d l e
was slightly bent (the skin was dimpled but not pene-
trated). We estimated the rat responses to five pin-prick
stimulus which were scored on an ordinal scale
[20,40,41] as follows: no response = 0; detection = 1;
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escape or attacking movements = 3; and all of the char-
acteristics of response 3, but with prolonged ipsilateral
facial grooming (> 3 strokes) = 4.
Effects of NR2 subunit antagonists on compression of the
trigeminal nerve root-induced mechanical allodynia and
hyperalgesia
The effects of NR2 subunit antagonists on mechanical
allodynia and hyperalgesia were evaluated on postopera-
tive day 14. Animals that displayed mechanical allodynia
and hyperalgesia following compression of the trigem-
inal nerve root were used for assessments. For intracis-
ternal injection, individual rats were anesthetized with
mixture of ketamine (0.2 g/kg) and xylazine (0.02 g/kg).
Anesthetized rats were individually mounted on a
stereotaxic frame and a polyethylene tube (PE10, CalyA-
dams, Parsippany, NJ) was implanted for intracisternal
injection on postoperative day 11, as described pre-
viously [42-45]. The polyethylene tube was inserted
through a tiny hole made in the atlantooccipital mem-
brane and dura, using a 27 gauge syringe needle. The
tip of the cannula was placed at the obex level. The
polyethylene tube was subcutaneously led to the top of
the skull and secured in place by a stainless steel screw
and dental acrylic resin. In the 72 hour recovery period
after surgery, NR2 subunit antagonists were intracister-
nally administered. For confirmation of the placement of
the intracisternal cannula and the extent of the spread
of the drugs, pontamine sky blue dye was injected at the
end of the tests. The animals that showed motor dys-
function or mal-position of the catheter after intracister-
nal catheterization were excluded from the analysis.
Mechanical allodynia and hyperalgesia was determined
15, 30, 60, 120, 180, 360 and 1440 min after intracister-
nal administration of NR2 subunit antagonists.
Administration of chemicals
The following compounds were used for intracisternal
injection of D-2-amino-5-phosphonopentanoate (D-
AP5), a non-selective NMDA site antagonist, (2R,4S)-4-
(3-Phosphonopropyl)-2-piperidinecarboxylic acid
(PPPA), a competitive NR2A antagonist, (aR,bS)-a-(4-
Hydroxyphenyl)-b-methyl-4-(phenylmethyl)-1-piperidi-
nepropanol maleate (Ro25-6981), a selective NR2B
antagonist, or (2S,3R)-1-(Phenanthren-2carbonyl)pipera-
zine-2,3-dicarboxylic acid (PPDA), a selective NR2C/
NR2D antagonist. All NMDA receptor related chemicals
were purchased from Tocris (Bristol, U.K.) and dissolved
in normal saline.
Immunohistochemistry
Some rats (n = 5 per group) were perfused through the
ascending aorta with 0.9% saline, followed by 4%
paraformaldehyde in 0.1 M PB (pH 7.4) under anesthe-
sia 3 hours after administration of NR2 subunit antago-
nists or vehicle. The caudal medulla were then dissected
out, postfixed in the same fixative at 4°C overnight, and
replaced with 30% sucrose in 0.1 M PB overnight.
Transverse frozen sections (free-floating, 30 μm) were
cut in a cryostat and processed for immunofluorescence.
All sections were blocked with 5% goat serum in 0.2%
Triton X-100 for 1 hour at room temperature and then
incubated overnight at 4°C with a rabbit polyclonal
phospho p38 antibody (1:300, Cell Signaling Technol-
ogy, Danvers, MA). The sections were then incubated
with Alexa 555-conjugated rabbit IgG antibody (1:400,
Invitrogen, Carlsbad, CA) for 2 h at room temperature.
The stained sections were then observed under fluores-
cence microscope (Zeiss Axioplan, Carl Zeiss, Germany).
Western blotting
Some rats (n = 5 per group) were sacrificed under
anesthesia 3 hours after administration of NR2 subunit
antagonists or vehicle. The dorsal part of caudal medulla
was then rapidly removed and frozen in liquid nitrogen.
Samples were sonicated with Biorupture (Cosmo Bio.,
Tokyo, Japan) in lysis buffer containing protease and phos-
phatase inhibitor cocktail (Thermo Scientific, Rockford,
IL). Protein concentrations of samples were measured
using a fluorometer (Invitrogen). For western blotting,
total proteins (30 μg) were separated by 4-12% gradient
NuPAGE Novex Bis-Tris gel (Invitrogen) and transferred
onto PVDF membrane by using the iBlot Dry blotting sys-
tem (Invitrogen). The membranes were then blocked with
5% non-fat milk in TBS with 0.1% Tween 20 for 1 hour at
room temperature and then incubated with p-p38 or total
p38 (both diluted 1:1000; Cell Signaling Technology) as
loading control at 4°C overnight. The blots were then
incubated with goat anti-rabbit horseradish peroxidase for
1 hour at room temperature. Membranes were developed
using the SuperSignal West Femto substrate (Pierce, Rock-
f o r d ,I L ) ,a n de x p o s e dt oX - r ay film. A computer image
analysis system (ImageJ; NIH, Bethesda, MD) was used for
quantification of the specific bands.
Rotarod test
Changes in motor performance, after the intracisternal
administration of D-AP5, PPPA, Ro 25-6981, or PPDA,
were measured using a rotarod (Ugo Basile, Comerio-
Varese, Italy), as described previously [20,40,46,47]. The
rotarod speed was increased to 16 rpm with the maxi-
m u mt i m es p e n to nt h er o ds e ta t1 8 0s e c o n d s .R a t s
received two or three training trials on two separate
days prior to testing for acclimatization. On the experi-
mental days, the time course of the motor performance
was examined before and after the intracisternal admin-
istration of NMDA receptor antagonists.
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Differences between groups were compared using analy-
sis of repeated measures ANOVA followed using LSD
post hoc analysis. Comparisons of p-p38 MAPK expres-
sion between NR2 subunits antagonists were performed
using one-way ANOVA followed using LSD post hoc
analysis. In all statistical comparisons, a P value of <
0.05 was used as the criterion for statistical significance.
All data are presented as the mean ± SEM.
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